272 related articles for article (PubMed ID: 32128688)
1. Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs.
Cusumano VT; May FP
J Gen Intern Med; 2020 Jun; 35(6):1870-1874. PubMed ID: 32128688
[TBL] [Abstract][Full Text] [Related]
2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
5. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
[TBL] [Abstract][Full Text] [Related]
6. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
8. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
9. Optimal Strategies for Colorectal Cancer Screening.
Jain S; Maque J; Galoosian A; Osuna-Garcia A; May FP
Curr Treat Options Oncol; 2022 Apr; 23(4):474-493. PubMed ID: 35316477
[TBL] [Abstract][Full Text] [Related]
10. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for colorectal cancer in a fecal immunochemical test-positive group: The National Health Insurance Service-National Health Screening Cohort.
Park JH; Cho KH; Choi J; Chun S; Lee JK; Cho H; Kim B
J Gastroenterol Hepatol; 2024 Jan; 39(1):74-80. PubMed ID: 37855299
[TBL] [Abstract][Full Text] [Related]
12. Impact of colorectal cancer screening on incidence, mortality and surgery rates: Evidences from programs based on the fecal immunochemical test in Italy.
Zorzi M; Urso EDL
Dig Liver Dis; 2023 Mar; 55(3):336-341. PubMed ID: 35999134
[TBL] [Abstract][Full Text] [Related]
13. Colon Cancer Screening - Is It Time Yet?
Bhurgri H; Samiullah S
J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
[TBL] [Abstract][Full Text] [Related]
14. Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.
Elangovan A; Skeans J; Lalani I; Ullah F; Roy A; Kaelber DC; Cooper GS; Sandhu DS
Dig Dis Sci; 2021 Aug; 66(8):2585-2594. PubMed ID: 32816217
[TBL] [Abstract][Full Text] [Related]
15. [Rates on the acceptance of colonoscopy, fecal immunochemical test and a novel risk-adapted screening approach in the screening programs of colorectal cancer as well as related associated factors].
Chen HD; Lu M; Liu CC; Zhang YH; Zou SM; Shi JF; Ren JS; Li N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Oct; 41(10):1655-1661. PubMed ID: 33297622
[No Abstract] [Full Text] [Related]
16. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
17. Patients without colonoscopic follow-up after abnormal fecal immunochemical tests are often unaware of the abnormal result and report several barriers to colonoscopy.
Cusumano VT; Corona E; Partida D; Yang L; Yu C; May FP
BMC Gastroenterol; 2020 Apr; 20(1):115. PubMed ID: 32306919
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).
Saito H; Kudo SE; Takahashi N; Yamamoto S; Kodama K; Nagata K; Mizota Y; Ishida F; Ohashi Y
Int J Colorectal Dis; 2020 May; 35(5):933-939. PubMed ID: 32034490
[TBL] [Abstract][Full Text] [Related]
19. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.
Meester RG; Zauber AG; Doubeni CA; Jensen CD; Quinn VP; Helfand M; Dominitz JA; Levin TR; Corley DA; Lansdorp-Vogelaar I
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1445-1451.e8. PubMed ID: 27211498
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
